THE DUDLEY GROUP NHS FOUNDATION TRUST FOI
|
|
- Theresa Long
- 5 years ago
- Views:
Transcription
1 THE DUDLEY GROUP NHS FOUNDATION TRUST FOI Question 2 Response shown in table below Question 4 - Please provide details of the number of applications for treatments used outside of their licensed indication (off-label) using the Cancer Drugs Fund made by your Trust for each month from April 2012 to November 2012 inclusive broken down by treatment and by indication - please find highlighted below in yellow. Vemurafenib Melanoma APRIL 2012 Bevacizumab (+IrMdG) CRC APRIL 2012 Panitumumab CRC APRIL 2012 Panitumumab CRC APRIL 2012 Bevacizumab (+IrMdG) CRC APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Bevacizumab (+Paclitaxel) mbreast (---) APRIL 2012 Vemurafenib Melanoma APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Bevacizumab (+Carbo/Taxane) Ovarian APRIL 2012 Everolimus mrcc APRIL 2012 Eribulin mbreast APRIL 2012 Imatinib GIST APRIL 2012 FolFOX = Oxaliplatin+5FU Pancreatic APRIL 2012 Cabazitaxel mcrpc MAY 2012 Abiraterone mcrpc MAY 2012
2 Lenalidomide Myelodysp 5q ETR MAY 2012 Bortezomib Myeloma MAY 2012 Fulvestrant HD (Faslodex) Breast MAY 2012 Cetuximab Head+Neck FEB 2012 Bevacizumab (+OxMdG) CRC MAY 2012 Abiraterone mcrpc MAY 2012 Bevacizumab (+OxMdG) CRC MAY 2012 Everolimus m.liver NET MAY 2012 Bevacizumab (+OxMdG) CRC JUNE 2012 Panitumumab CRC JUNE 2012 Bevacizumab (+OxMdG) CRC JUNE 2012 Rituximab Maintenance MCLymphoma JUNE 2012 Vemurafenib Melanoma JUNE 2012 Fulvestrant HD (Faslodex) Breast JUNE 2012 Fulvestrant HD (Faslodex) Breast JUNE 2012 Fulvestrant HD (Faslodex) Breast JULY 2012 Lapatinib (with Capecitabine) mbreast JULY 2012 Fulvestrant HD (Faslodex) Breast JULY 2012 FolfirinOX (5FU+Fol+Irin+OX) Pancreatic JULY 2012 Everolimus Caecal NET JULY 2012 Bevacizumab (+OxMdG) CRC JULY 2012 Bevacizumab (+OxMdG) CRC JULY 2012 Brentuximab Vedotin Hodgkins MAY 2012 Bendamustine + Rituximab CLL JULY 2012 Eribulin mbreast AUG 2012
3 Bevacizumab (+OxMdG) CRC SEPT 2012 Bevacizumab (+OxMdG) CRC AUG 2012 Ipilimumab Melanoma AUG 2012 FolFOX = Oxaliplatin+5FU Pancreatic SEPT 2012 Vemurafenib Melanoma SEPT 2012 Bevacizumab (+OxMdG) CRC SEPT 2012 Paclitaxel Albumin (Abraxane) Breast SEPT 2012 Bevacizumab (+OxMdG) CRC SEPT 2012 Rituximab Maintenance MCLymphoma SEPT 2012 Ipilimumab Melanoma SEPT 2012 Bevacizumab (+IrMdG) CRC SEPT 2012 Lapatinib (with Capecitabine) mbreast SEPT 2012 Rituximab Maintenance MCLymphoma SEPT 2012 Imatinib GIST OCT 2012 Bevacizumab (+IrMdG) CRC OCT 2012 Panitumumab CRC OCT 2012 Pemetrexed Maintenance NSCLC OCT 2012 Fulvestrant HD (Faslodex) Breast OCT 2012 Bevacizumab (+OxMdG) CRC OCT 2012 Ipilimumab Melanoma OCT 2012 Eribulin mbreast NOV 2012 Bevacizumab (+OxMdG) CRC NOV 2012 FolFOX = Oxaliplatin+5FU Pancreatic NOV 2012 Bevacizumab (+IrMdG) CRC NOV 2012 Bevacizumab (+IrMdG) CRC NOV 2012 Cabazitaxel mcrpc NOV 2012 Fulvestrant HD (Faslodex) Breast NOV 2012
4 Vemurafenib Melanoma NOV 2012 Panitumumab mcrc NOV 2012 Panitumumab mcrc NOV 2012 FolfirinOX (5FU+Fol+Irin+OX) Pancreatic NOV 2012 Rituximab Maintenance MCLymphoma NOV 2012
5 Trust Headquarters Russells Hall Hospital Dudley West Midlands DY1 2HQ Date: 17/01/2013 FREEDOM OF INFORMATION ACT Ref: FOI/ With reference to your FOI request that was received on 21/12/2012 in connection with 'Cancer Drug Fund'. Your request for information has now been considered and the information requested is enclosed. Further information about your rights is also available from the Information Commissioner at: Information Commissioner Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Tel: Fax: Yours sincerely Information Governance Manager Room 34a, First Floor, Esk House, Russells Hall Hospital, Dudley, DY1 2HQ FOI@dgh.nhs.uk
6 Please find the responses to your request, in turn, below. Please confirm or deny whether your trust has submitted applications for treatments using the Cancer Drugs Fund between April 2012 and November 2012 inclusive. Confirmed Please supply details of the number of applications that your trust has submitted for treatments using the Cancer Drugs Fund during each month between April 2012 and November 2012 inclusive, broken down by cancer treatment and indication. Please find the response to question 2 attached Please confirm or deny whether your trust has submitted applications for treatments to be used outside of their licensed indication (off-label) using the Cancer Drugs Fund between April 2012 and November 2012 inclusive. Confirmed Please provide details of the number of applications for treatments used outside of their licensed indication (off-label) using the Cancer Drugs Fund made by your trust for each month from April 2012 to November 2012 inclusive, broken down by treatment, and by indication. Please find the response to question 4 attached
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationCancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationThe Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationCancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
More informationNational Cancer Drugs Fund List Ver2.1
National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationLisa Evans. 9 May Freedom of Information Request Ref: FOI
Trust HQ Rikenel Montpellier Gloucester GL1 1LY Direct Tel: 01452 894266 E-mail: 2gnft.Information-Freedom@nhs.net Website: www.2gether.nhs.uk 9 May 2018 Freedom of Information Request Ref: FOI 038-1819
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationNational Cancer Drugs Fund List Ver4.4
National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
More informationNational Cancer Drugs Fund List Ver4.0
National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationDate: 13 November Our Ref: FOI Dear Requester
Date: November 205 Chelsea and Westminster Hospital Information Governance Team Chelsea Harbour Harbour Yard Unit, st Floor London SW0 0XD www.chelwest.nhs.uk Our Ref: FOI 205-9 Dear Requester Thank you
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationYou requested information regarding the diagnostic imaging provision. Specifically you asked:
Executive Corridor Memorial Hospital Switchboard Tel: 01325 38 0100 Foundation Trust Office: 01325 74 3625 Corporate Records Office: 01325 74 3700 Request for Information Reference: 10.16.08 Direct line:
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationMolecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationRequest under the Freedom of Information Act 2000 (FOIA)
Our Ref: 002338/14 Freedom of Information Section Nottinghamshire Police HQ Sherwood Lodge, Arnold Nottingham NG5 8PP Tel: 101 Ext 800 2507 Fax: 0115 967 2896 02 May 2014 Request under the Freedom of Information
More information20 June 2018 Our Ref: RFI 23569
Information Governance 20 June 2018 Our Ref: RFI 23569 Dear Freedom of Information Act 2000 Information in Relation to Translator Costs I am writing to confirm that the South Eastern Health & Social Care
More informationYour Ref: VY March Dear. Your Request for Information
Your Ref: VY 207 31 March 2014 NHS Vale of York CCG c/o North Yorkshire and Humber CSU Health House Grange Park Lane Willerby East Yorkshire HU10 6DT Telephone: (01482) 672191 Dear E-mail: VoYCCG.FOI@nhs.net
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationNICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationSuffolk Constabulary has considered your request for information and the response is below.
Freedom of Information Request Reference N o : FOI 005896-17 I write in connection with your request for information received by Suffolk Constabulary on the 31 July 2017 in which you sought access to the
More information2. What is the average cost of a cycle of an IVF cycle funded by the CCG and what does that include?
Communications & Engagement Team 1st Floor North Point Cardinal Square 10 Nottingham Road Derby DE1 3QT Tel: 01332 888080 Fax: 01332 868 898 www.southernderbyshireccg.nhs.uk Our ref: 340/16 Tuesday 26
More informationFREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK
Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION
More information5 December 2016 Our Ref: RFI Freedom of Information Act 2000 Provision of Services for Attention Deficit Hyperactivity Disorder (ADHD)
Information Governance 5 December 2016 Our Ref: RFI 18852 Dear Freedom of Information Act 2000 Provision of Services for Attention Deficit Hyperactivity Disorder (ADHD) I am writing to confirm that the
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationNorth of England Cancer Drugs Approval Group (NECDAG) Cumulative Table of Decisions August 2012
Notes: This document is updated every 2 to 3 months; please check our website www.cancernorth.nhs.uk for latest version. This document does not all contain Interim Cancer Drugs Fund s, i.e. decisions made
More informationNEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria
NEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria The information in this document is a summary of the funding criteria for the New Drug Funding
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationCPT Service Description Effective Date
Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,
More informationBest of ASCO. 38 accc-cancer.org September October 2017 OI
Best of ASCO 2017 38 accc-cancer.org September October 2017 OI BY CARY A. PRESANT, MD, FACP, FASCO SCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationThe Trust does not record electronically the number of patients who are treated by laser for a condition.
Ref: FOI/CAD/ID 3224 06 April 20 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act 2000
More informationPrivacy Notice Sign Language Interpreting Service
22 Forest Road West, Nottingham NG7 4EQ Website: www.nottsdeaf.org.uk Email: nds@nottsdeaf.org.uk Tel: 0115 9700516 (voice/minicom) SMS: 0781 7275253 Fax: 0115 9423096 Sign Language Interpreting Service
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationGenomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education
Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education Aims of this session Understand how genomic information will change your clinical practice Remind
More informationINJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]
Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationI am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Adult hearing services.
Ref: FOI/CAD/ID 2831 06 April 2016 Please reply to: FOI Administrator Trust Management Service Centre Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of
More informationRESEARCH. Courtney Davis, 1 Huseyin Naci, 2 Evrim Gurpinar, 2 Elita Poplavska, 3 Ashlyn Pinto, 2 Ajay Aggarwal 4,5
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 Courtney Davis,
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationThe Clinical Research E-News
Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationPhase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMENT AT 1-800- 710-4674 Phase 1 REFMAL 381 (Phase 1 open at BAM only) Phase
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationClinical Trials OPEN to ENROLLMENT
CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II
More informationFREEDOM OF INFORMATION ACT 2000 Dudley CCG: Prescribing of Antibiotics Ref: RFI0861
Freedom of Information Team Dudley CCG 17 November 2017 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU FREEDOM OF INFORMATION ACT 2000 Dudley CCG: Prescribing
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationLecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents
Lecture 8: Antibodies & Antibody Conjugates - targeted cell killing agents Monoclonal antibodies can be identified quickly by the mab at the end of their name. They are can be naked or conjugated depending
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
More informationFREEDOM OF INFORMATION ACT 2000 Dudley CCG: Adult Hearing Services (linked to former FOI RFI0598) - Ref: RFI0705
Freedom of Information Team Dudley CCG 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU Response by email 10 May 2017 FREEDOM OF INFORMATION ACT 2000 Dudley CCG:
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationOPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationFREEDOM OF INFORMATION DECISION NOTICE. FOI Reference Number: 999
Scarsdale Nightingale Close Newbold Chesterfield S41 7PF Tel.: 01246 514048 Date: 7 January 2019 FREEDOM OF INFORMATION DECISION NOTICE Dear Sir / Madam, FOI Reference Number: 999 I refer to your email
More informationTHE TWENTY LESSONS LEARNT FROM THE DEVELOPMENT OF MOLECULAR- TARGETED THERAPIES. Prepared by: N. Kotecki, MD G. Argilés, MD, PhD A.
THE TWENTY LESSONS LEARNT FROM THE DEVELOPMENT OF MOLECULAR- TARGETED THERAPIES Prepared by: N. Kotecki, MD G. Argilés, MD, PhD A. Awada, MD, PhD DISCLOSURES Nuria Kotecki has reported no conflicts of
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationBone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
More informationStage 4 breast cancer life expectancy
P ford residence southampton, ny Stage 4 breast cancer life expectancy Breast cancer life expectancy depends on the stage of breast cancer, presence of metastasis, immune system of a person and the preferred
More informationCancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationADCs The year in review and 2018 outlook
ADCs The year in review and 2018 outlook INTRO Antibody-drug conjugates (ADCs), are agents that consists of an immune substance, such as a monoclonal antibody, antigen or an immunoglobulin, and covalently
More informationCancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
More informationConflict of Interest All Trials NOT Permanently Closed (as of February 2, 2017)
BRAIN Conflict of Interest All Trials NOT Permanently Closed (as of February 2, 2017) CE2 CE5 CEC1 CEC2 CEC3 Phase III Intergroup Randomized Comparison of Radiation Alone versus Preradiation Chemotherapy
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationMedia Release. Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO. Basel, 11 May 2015
Media Release Basel, 11 May 2015 Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO Roche medicines to be featured in more than 275 abstracts during ASCO 2015 New pivotal
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationPhase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT 1-800- 710-4674 Phase 1 GI- 219: BBI608-246 (pending 1 st Qtr) Phase
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationOpdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?
EMA/852560/2018 EMEA/H/C/003985 An overview of Opdivo and why it is authorised in the EU What is Opdivo and what is it used for? Opdivo is a cancer medicine used to treat the following: melanoma, a type
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer Jefferies 2015 Global Healthcare Conference Ron Squarer, Chief Executive Officer June 2, 2015 Safe Harbor Statement Forward-looking
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationIRB INDICATION Number ENROLLED
Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics
More informationActive Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationFREEDOM OF INFORMATION ACT 2000 Dudley CCG - Growth Hormone Prescribing- Ref: RFI0222
Freedom of Information Team Dudley CCG Response by email 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU 27 th August 2015 FREEDOM OF INFORMATION ACT 2000 Dudley
More information